NASDAQ · PHARMACEUTICAL PREPARATIONS · LARGE CAP
Schrodinger, Inc. SDGR
7 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$255.9M
▲ 23.3% vs FY2024
EPS · FY25
$-1.41
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-26.3%
Net margin · FY25
-40.4%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 255.9M
Revenue, FY2025 · full 7-year series below
Revenue
Net income
The company lost 40 cents on every revenue dollar this year.
Per share
USD -1.41
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-26.3%
Return on equity, FY2025
ROE
Operating margin-65.2%
Net margin-40.4%
Return on assets-13.3%
Each USD of equity lost 26 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+18.8% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+12.2%
+18.8%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
—
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 726.2M
total assets, end of FY2025
Total assetsUSD 726.2M
EquityUSD 364.1M
CashUSD 230.5M
Current ratio2.75×
Equity funds 50% of total assets.
History
7 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
Revenue $B
0.3
0.2
0.2
0.2
0.1
0.1
0.1
Operating income $B
−0.2
−0.2
−0.2
−0.1
−0.1
−0.1
−0.0
EBITDA $B
−0.2
−0.2
−0.2
−0.1
−0.1
−0.1
−0.0
Income tax $B
0.0
0.0
0.0
0.0
0.0
0.0
−0.0
Net income $B
−0.1
−0.2
0.0
−0.1
−0.1
−0.0
−0.0
EPS, diluted $
−1.41
−2.57
0.54
−2.10
−1.42
−0.41
−4.09
Dividend / sh $
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
ROE %
−26.3
−38.6
8.2
−29.7
−17.0
−9.2
·
Shares out B
·
·
0.06
0.01
0.01
0.01
0.00
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
28 of 28
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed